Haemonetics Corporation

Symbol: HAE

NYSE

93.33

USD

Market price today

  • 37.4340

    P/E Ratio

  • 0.2241

    PEG Ratio

  • 4.74B

    MRK Cap

  • 0.00%

    DIV Yield

Haemonetics Corporation (HAE) Stock Split, History Data

Working capital analysis

In terms of working capital, Haemonetics Corporation maintains a healthy position. The total current assets of the company are valued at $769722000. This represents a growth rate of 1.811% compared to the previous year. Breaking down the current assets, the cash and investments are worth $284466000, exhibiting a growth rate of 9.622% year-on-year. The receivables, another significant portion of the current assets, are valued at $179142000. The year-on-year growth rate for receivables is 12.402%. The inventory, which forms a critical part of the assets, is valued at $259379000. This represents a healthy year-on-year growth of -11.483% On the liabilities side, the company's current liabilities total $251816000. This reflects a growth rate of -43.062% over the previous year, indicating the company's financial obligations are well under control.

202320222021202020192018
Cash and investments
284.47
259.50
192.31
137.31
169.35
180.17
Receavebles
179.14
159.38
127.56
165.21
185.03
151.23
Inventory
259.38
293.03
322.61
270.28
194.34
160.80
Other
46.73
44.13
51.07
30.84
27.41
28.98
Total Current Assets
769.72
756.03
693.55
603.64
576.12
521.18
Acc Payable
63.93
58.37
50.29
50.73
63.36
55.27
Short Term Debt
11.78
214.15
17.02
76.98
27.67
194.26
Other Current Liab
145.89
137.92
159.91
127.75
117.45
109.36
Current Liabilities
251.82
442.27
253.50
284.30
235.76
384.70

Capital Structure

When examining the capital structure of Haemonetics Corporation, it is clear that the company manages a robust portfolio. The value of their total assets clocks in at $2200428000. When juxtaposed with the previous year, this marks a growth rate of 17.165%, showcasing the company's ability to steadily grow its asset base. Turning to liabilities, the company has total liabilities amounting to $1257109000. Compared to the prior year, this reflects a growth rate of 14.066%. The long-term debt forms a sizable part of these liabilities, coming in at $856849000. Over the last year, the long-term debt has grown by 13.216%. On the asset side, the cash and equivalent reserves are worth $193978000. The year-on-year growth of these reserves is -13.403%. The company's common stock, another important asset, holds a value of $508000, growing at a rate of 0.794% from the previous year. Finally, the company's retained earnings stand at $340099000, marking a growth rate of 51.976% year-over-year. These earnings represent the profits that Haemonetics Corporation has chosen to reinvest in the business rather than distribute as dividends.

Total Assets

$2,200.43

Total liabilities

$1,257,109,000.00

Long term debt

$856.85

Cash and eqv

$193,978,000.00

Goodwill

$555.00

Retained earnings

$340,099,000.00

Common stock

$0.00

Enterprise Value

$15.73

Net earnings per share (EPS)

Haemonetics Corporation has an EPS of $2.50, which signifies the profit allocated per share of common stock. With a growth rate of 48.810% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.

YearsQ1Q2Q3Q4Total
20230.810.490.620.582.50
20220.390.650.450.192.33
2021-0.090.29--0.22-0.02
20200.210.950.630.342.13
2019-0.170.740.590.41.56
2018-0.05410.360.360.220.89
20170.380.38-0.12-0.98-0.34
2016-0.20.390.3-0.170.32
2015-0.00520.25-1.17-0.0568-0.99
2014-0.07050.150.310.20.59
2013-0.150.320.310.240.72
20120.190.130.190.350.86
20110.330.280.40.41.77
20100.360.43-0.07750.87
20090.350.350.360.271.33
20080.280.30.320.261.16
20070.240.220.280.371.11
20060.210.0250.320.310.87
20050.250.210.220.181.39
20040.20.18-0.190.57
20030.110.120.190.09240.51
20020.140.140.220.140.64
20010.190.190.0450.140.56
20000.13-0.30.180.01510.03
19990.110.110.090.110.55
19980.0950.1--0.45-0.25
19970.120.075-0.220.150.12
19960.170.160.130.160.62
19950.160.170.160.150.64
19940.140.150.150.150.59
19930.120.140.140.120.52
19920.0950.110.120.09740.43
19910.0650.0750.0800.21
19900.0650.0650.065-0.21

Haemonetics Corporation (HAE) stock split history

Understanding the historical stock splits of Haemonetics Corporation (HAE) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on December 03, 2012 with a ratio of 2:1. Throughout its history, the company has undergone 2 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.

DateSplit Ratio
03 December 20122:1
11 January 19932:1

Frequently Asked Question

What is the latest historical split date of the company?

The latest historical split date is N/A.

What is firm free cah flow per share (FCF per share)?

The free cah flow per share (FCF per share) is 2.536.

What is company revenue per share?

The company revenue per share is 0.134.

What are firm earnings per share?

The firm earnings per share is 0.786.

What is Haemonetics Corporation (HAE) ROIC (return on capital)?

Haemonetics Corporation (HAE) ROIC (return on capital) is 0.088.

What is dividend per share figure?

The dividend per share is 0.000

What is enterprise plowback ratio?

Haemonetics Corporation (HAE) plowback ratio is N/A

What is firm enterprise value (EV)?

The enterprise value (EV) is 15.734

What is company debt to equity ratio?

The debt to equity ratio is 0.923

What are debt ratio numbers?

The debt ratio is 0.396

What is company price to sales ratio?

The price to sales ratio is 3.732